

Special Issue

Influenza Vaccination for People with Chronic Diseases

Message from the Guest Editors

The effect of influenza vaccination on decreasing the risk of influenza virus infection has been well reported before. Moreover, via the protection from the influenza vaccine, the risk of mortality and other complications of influenza virus infection could be significantly lowered. Therefore, it is highly recommended to receive the influenza vaccine annually, especially for high-risk populations such as patients with chronic diseases, the elderly, and healthcare providers. In addition to the protective effect from infection, the other potential benefits of influenza vaccination have also been demonstrated in previous research. However, detailed mechanism and clinical data on the additional effects of influenza vaccination among patients with chronic diseases are still lacking. We are pleased to invite you to submit research articles regarding the effectiveness and potential mechanism of the influenza vaccine among patients with chronic diseases. Clinical observational studies, randomized control trials, and basic molecular/animal investigation are all welcome for submission.

Guest Editors

Prof. Dr. Ju-Chi Liu
Dr. Wen-Rui Hao
Dr. Chun-Chao Chen

Deadline for manuscript submissions

closed (25 May 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/134407

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).